Anti-DLL4 Antibody (Enoticumab)
Catalog No.
F1543
Anti-DLL4 Antibody (Enoticumab)
Featured Products
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway that regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Enoticumab has specific in vivo activity in an ovarian xenograft model. EGN421 (2.5mg/kg, once a week) resulted in 86% and 83% tumor growth inhibition in subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models in mice, respectively.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.48 kDa
Dry ice
1192578-27-0
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
SAR153192, REGN421
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q9NR61
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human DLL4 His at 2 ug/mL can bind Anti-DLL4 Antibody (Enoticumab)
DLL4
Please avoid freeze-thaw cycles.